# Tutivia™ study confirms predictive value in transplant care

- Link: https://www.directorstalkinterviews.com/tutivia-study-confirms-predictive-value-in-transplant-care/4121236282
- Published: 2026-01-27T14:13:00+00:00
- Author: Amilia Stone

[Verici Dx](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)
completed a pivotal clinical validation study for Tutivia™, a test designed to support
early risk assessment in kidney transplant recipients. Conducted across thirteen
centres in the United States, Europe and Australia, the prospective, blinded study
evaluated the performance of Tutivia™ in predicting acute rejection (AR) within 
the first six months after transplant.

The study assessed 151 patients using a proprietary RNA sequencing platform that
analyses gene expression associated with kidney injury, immune response, and graft
protection. Tutivia™ applies an AI-driven algorithm to generate a patient-specific
risk score between 0 and 100. A score above 50 is interpreted as high risk for acute
rejection, providing clinicians with an actionable metric to tailor post-transplant
care.

[VALIDATION-STUDY](https://www.directorstalkinterviews.com/wp-content/uploads/2026/01/VALIDATION-STUDY.pdf)
[Download](https://www.directorstalkinterviews.com/wp-content/uploads/2026/01/VALIDATION-STUDY.pdf)

_**[Verici Dx Plc](https://www.directorstalkinterviews.com/company/verici-dx-plc/vrci.l)**(
LON:VRCI) is developing a complementary suite of proprietary, leading-edge tests
forming a kidney transplant diagnostics platform for personalised patient and organ
response risk to assist clinicians in medical management for improved patient outcomes._

Share on:
